Welcome to our dedicated page for DOMINARI HOLDINGS news (Ticker: DOMH), a resource for investors and traders seeking the latest updates and insights on DOMINARI HOLDINGS stock.
Dominari Holdings Inc. (DOMH) delivers cutting-edge developments in biotechnology and financial services through its diversified operations. This news hub provides investors and stakeholders with timely updates on the company’s therapeutic research, market activities, and strategic initiatives.
Access comprehensive coverage of DOMH’s progress in oncology drug development, including updates on clinical trials targeting pancreatic cancer and leukemia. Track financial services milestones through Dominari Securities LLC’s underwriting activities and technology investments in AI infrastructure.
The page consolidates official press releases covering earnings reports, partnership announcements, and regulatory developments. Users will find verified information on therapeutic advancements, capital market participation, and emerging technology ventures.
Bookmark this resource for streamlined access to DOMH’s latest achievements in small-molecule research and financial market operations. Regularly updated content ensures informed decision-making for all stakeholders monitoring this innovative holding company.
On March 21, 2023, Dominari Holdings Inc. (Nasdaq: DOMH) announced that FINRA has approved the change in ownership allowing its subsidiary, Dominari Financial Inc., to fully acquire Fieldpoint Private Securities LLC. This approval marks a significant step in Dominari's transition into fintech and financial services, following a previously disclosed agreement to purchase Fieldpoint. The final closing is expected within five business days post-FINRA approval. The move aligns with Dominari's strategic pivot from its earlier focus on developing therapeutics.
Dominari Holdings Inc. (Nasdaq: DOMH) has updated its $2 million share repurchase program, initiated on December 5, 2022. On March 20, 2023, the company purchased 4,900 shares at $3.3759 each. The repurchase plan allows for additional shares to be bought based on market conditions and regulatory guidelines. While the company has transitioned from a focus on therapeutics to fintech through Dominari Financial Inc., it continues to develop its therapeutic pipeline via Aikido Labs, LLC. This strategic shift may enhance shareholder value and confidence in future growth.
Dominari Holdings Inc. (Nasdaq: DOMH) announced an update on its $2 million share repurchase program, initially authorized on December 5, 2022. On March 16, 2023, the company repurchased 5,000 shares at $3.487 each. The repurchase strategy will continue as per market conditions and regulatory guidelines. Dominari, which recently transitioned from drug development to financial services, aims to enhance shareholder value through this buyback initiative.
Dominari Holdings Inc. (Nasdaq: DOMH) announced updates on its $2 million share repurchase program initiated on December 5, 2022. On March 14, 2023, the Company repurchased 5,000 shares at $4.0119 each. The share buyback will continue subject to market conditions and regulations. The Company, transitioning from a therapeutics focus to fintech, plans to operate its new business through Dominari Financial Inc. This shift follows the acquisition of a registered broker-dealer. The buyback is aimed at enhancing shareholder value and reflects confidence in the company's future.
Dominari Holdings Inc. (Nasdaq: DOMH) announced significant progress in its stock buyback and transition to a financial services model. On March 13, 2023, the company acquired 3,400 shares at an average price of $4.1143. Since initiating the buyback, over 644,000 shares have been retired, reducing outstanding shares to below 4.9 million. CEO Anthony Hayes emphasized that the buyback increases shareholder ownership interest. The company is also advancing its fintech transition, seeking FINRA approval for the acquisition of FieldPoint's broker-dealer business, which promises enhanced technology and investment capabilities.
Dominari Holdings Inc. (Nasdaq: DOMH) announced an update on its $2 million share repurchase program initiated on December 5, 2022. On March 8, 2023, the company repurchased 5,000 shares at an average price of $4.1979. The company may continue repurchases depending on market conditions and regulatory guidelines. Dominari, transitioning to focus on fintech and financial services, operates through its subsidiary, Dominari Financial Inc., while still developing therapeutics through Aikido Labs, LLC. The forward-looking statements in the release express potential future risks and uncertainties.
Dominari Holdings Inc. (Nasdaq: DOMH) announced an update on its $2 million share repurchase program authorized on December 5, 2022. On March 6, 2023, the Company repurchased 4,499 shares at $4.3891 each. Future repurchases may occur based on market conditions and regulatory limitations. The Company is transitioning its focus from therapeutics to fintech and financial services through its subsidiary, Dominari Financial Inc., after acquiring a registered broker-dealer. Dominari also continues to develop therapeutics through Aikido Labs, LLC.
Dominari Holdings Inc. (Nasdaq: DOMH) announced an update on its $2 million share repurchase program, initiated on December 5, 2022. The company purchased 5,000 shares at $4.2658 per share on March 2, 2023. Future repurchases will depend on market conditions, corporate strategies, and regulatory limitations. Dominari, previously focused on anticancer and antiviral therapeutics, is transitioning to fintech through its subsidiary, Dominari Financial Inc. The company remains involved in its therapeutic ventures via Aikido Labs, LLC.
Dominari Holdings Inc. (Nasdaq: DOMH) announced updates on its $2 million share repurchase program authorized on December 5, 2022. As of February 28, 2023, the Company repurchased 4,603 shares at $3.7434 per share. The repurchase may continue periodically, influenced by market conditions and regulatory limitations. The Company, rebranded from Aikido Pharma, is transitioning its focus to fintech through its subsidiary, Dominari Financial Inc., while still pursuing therapeutic development via Aikido Labs, LLC. This dual focus aims to enhance long-term shareholder value.
Dominari Holdings Inc. (Nasdaq: DOMH) announced an update regarding its $2 million share repurchase program authorized on December 5, 2022. On February 27, 2023, the company bought 4,855 shares at $3.6941 per share. Further repurchases may occur based on market conditions and regulatory limitations. Dominari, formerly focused on therapeutics, is transitioning to fintech services through its subsidiary, Dominari Financial Inc., while still developing its healthcare portfolio through Aikido Labs, LLC.
